News
News & Views Published: August 2000 From parathyroid to thymus, via glial cells Rudi Balling & Reinhold G. Erben Nature Medicine 6, 860–861 (2000) Cite this article ...
A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...
News Medical on MSN6d
Timepoint at which B cells transform into leukemic cells impacts treatment outcomesNew findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...
T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive form of blood cancer that can occur in both children and ...
Hippo pathway controls biopterin metabolism to shield adjacent cells from ferroptosis in lung cancer
Heterogeneous Hippo pathway (YAP/TAZ) activation in lung adenocarcinoma drives tumor progression by enabling ferroptosis ...
AZD0486 demonstrated encouraging safety and dose-dependent efficacy in heavily pretreated adolescent and adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), according to ...
The field of cellular immunotherapy has undergone a profound transformation in recent years, with autologous chimeric antigen receptor (CAR) T-cell therapies emerging as the standard-of-care option ...
Over the past decade, several novel immunotherapies have transformed the treatment landscape of relapsed or refractory B-cell acute lymphoblastic leukaemia. In the pivotal TOWER trial, blinatumomab—a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback